NCT05226923View on ClinicalTrials.gov

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2022

Conditions
Bacterial Infections
Interventions
DRUG

KSP-1007

Single and multiple doses, intravenous administration

OTHER

Placebo:0.9% sodium chloride

Single and multiple doses, intravenous administration

DRUG

Meropenem

Multiple doses, intravenous administration

Trial Locations (1)

66219

PRA Health Sciences, Lenexa

All Listed Sponsors
lead

Sumitovant Biopharma, Inc.

INDUSTRY

NCT05226923 - Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects | Biotech Hunter | Biotech Hunter